Renin-angiotensin system blockade in patients with chronic kidney disease : benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction
Management of hypertension and albuminuria are considered among the primary goals of treatment to slow the progression of chronic kidney disease (CKD). Renin-angiotensin system (RAS) blockers, i.e., angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the main drugs to achieve these goals. Seminal studies have showed that RAS blockers present significant renoprotective effects in CKD patients with very high albuminuria. In post hoc analyses of such trials, these renoprotective effects appeared more robust in patients with more advanced CKD. However, randomized trials specifically addressing whether RAS blockers should be initiated or maintained in patients with advanced CKD are scarce and do not include subjects with normoalbuminuria, thus, many clinicians are unconvinced for the beneficial effects of RAS blockade in these patients. Further, the fear of hyperkalemia or acute renal decline is another factor due to which RAS blockers are usually underprescribed and are easily discontinued in patients with more advanced CKD; i.e., those in Stages 4 and 5. This review summarizes evidence from the literature regarding the use of RAS blockers in patients with advanced CKD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of human hypertension - 35(2021), 6 vom: 02. Juni, Seite 499-509 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Loutradis, Charalampos [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Angiotensin Receptor Antagonists |
|---|
| Anmerkungen: |
Date Completed 23.09.2021 Date Revised 11.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41371-021-00504-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM322117356 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM322117356 | ||
| 003 | DE-627 | ||
| 005 | 20231225181343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41371-021-00504-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1073.xml |
| 035 | |a (DE-627)NLM322117356 | ||
| 035 | |a (NLM)33654237 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Loutradis, Charalampos |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Renin-angiotensin system blockade in patients with chronic kidney disease |b benefits, problems in everyday clinical use, and open questions for advanced renal dysfunction |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.09.2021 | ||
| 500 | |a Date Revised 11.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Management of hypertension and albuminuria are considered among the primary goals of treatment to slow the progression of chronic kidney disease (CKD). Renin-angiotensin system (RAS) blockers, i.e., angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) are the main drugs to achieve these goals. Seminal studies have showed that RAS blockers present significant renoprotective effects in CKD patients with very high albuminuria. In post hoc analyses of such trials, these renoprotective effects appeared more robust in patients with more advanced CKD. However, randomized trials specifically addressing whether RAS blockers should be initiated or maintained in patients with advanced CKD are scarce and do not include subjects with normoalbuminuria, thus, many clinicians are unconvinced for the beneficial effects of RAS blockade in these patients. Further, the fear of hyperkalemia or acute renal decline is another factor due to which RAS blockers are usually underprescribed and are easily discontinued in patients with more advanced CKD; i.e., those in Stages 4 and 5. This review summarizes evidence from the literature regarding the use of RAS blockers in patients with advanced CKD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Angiotensin Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 700 | 1 | |a Price, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Ferro, Charles J |e verfasserin |4 aut | |
| 700 | 1 | |a Sarafidis, Pantelis |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of human hypertension |d 1996 |g 35(2021), 6 vom: 02. Juni, Seite 499-509 |w (DE-627)NLM012646121 |x 1476-5527 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2021 |g number:6 |g day:02 |g month:06 |g pages:499-509 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41371-021-00504-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2021 |e 6 |b 02 |c 06 |h 499-509 | ||